| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Instituto Nacional de Enfermedades Respiratorias, México, DF, Mexico
Study objective: We compared the long-term efficacy of the combination of colchicine and/or D-penicillamine with prednisone, in comparison to prednisone alone in patients with idiopathic pulmonary fibrosis (IPF).
Design: Nonrandomized prospective study in patients with IPF confirmed by biopsy specimen.
Setting: National Institute of Respiratory Diseases, Mexico.
Patients: Fifty-six IPF patients were included in this study. Patients received either colchicine/prednisone (n=19), D-penicillamine/prednisone (n=11), D-penicillamine/colchicine/prednisone (n=11), or prednisone alone (n=15). Prednisone therapy was started at 1.0 mg/kg/d for 1 month followed by a biweekly taper to a maintenance dose of 15 mg/d. Colchicine was administered at a daily dose of 1.0 mg, and D-penicillamine was given at a daily dose of 600 mg.
Measurements and results: Response to therapy was assessed by changes in lung function test results as measured by total and vital lung capacities, arterial blood gas analysis at rest breathing room air, and survival. No significant differences either in lung mechanics or in arterial gases were found in any group relative to the baseline measurement. Thirteen of the 56 patients died during the first 2 years, and 29 were dead at 5 years follow-up. Comparison of survival curves by Cox regression model showed no statistically significant difference among the four groups. Known side effects attributable to prednisone were more common and severe than those attributable to the other drugs.
Conclusions: Our results suggest that neither colchicine nor D-penicillamine modified the progressive course of prednisone-treated IPF, and that the search for new drugs is imperative.
Key Words: idiopathic pulmonary fibrosis • fibrosing alveolitis • colchicine • D-penicillamine • prednisone corticosteroids
Submitted on January 27, 1998
Accepted on May 14, 1998
This article has been cited by other articles:
|
|
 |
|
  G. Raghu Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur. Respir. J., September 1, 2006; 28(3): 463 - 465. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Walter, H. R. Collard, and T. E. King Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Nathan Therapeutic Intervention: Assessing the Role of the International Consensus Guidelines Chest, November 1, 2005; 128(5_suppl_1): 533S - 539S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bouros and K. M. Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur. Respir. J., October 1, 2005; 26(4): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Pacanowski and G. W Amsden Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis Ann. Pharmacother., October 1, 2005; 39(10): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khalil and R. O'Connor Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. KING JR., M. I. SCHWARZ, K. BROWN, J. A. TOOZE, T. V. COLBY, J. A. WALDRON JR., A. FLINT, W. THURLBECK, and R. M. CHERNIACK Idiopathic Pulmonary Fibrosis . Relationship between Histopathologic Features and Mortality Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Gross and G. W. Hunninghake Idiopathic Pulmonary Fibrosis N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525. [Full Text] [PDF]
|
|
|
|
|
|
M. Selman Idiopathic Pulmonary Fibrosis Challenges for the Future Chest, July 1, 2001; 120(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
|
|
S. Blivet, F. Philit, J. M. Sab, B. Langevin, M. Paret, C. Guerin, and D. Robert Outcome of Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU for Respiratory Failure Chest, July 1, 2001; 120(1): 209 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Selman, T. E. King Jr., and A. Pardo Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Ann Intern Med, January 16, 2001; 134(2): 136 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Selman, V. Ruiz, S. Cabrera, L. Segura, R. Ramirez, R. Barrios, and A. Pardo TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L562 - L574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. DOUGLAS, J. H. RYU, and D. R. SCHROEDER Idiopathic Pulmonary Fibrosis . Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1172 - 1178. [Abstract] [Full Text]
|
|
|
|
|
|
T. King Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment . International Consensus Statement Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 646 - 664. [Full Text]
|
|
|
|
|
|
R. J. MASON, M. I. SCHWARZ, G. W. HUNNINGHAKE, and R. A. MUSSON Pharmacological Therapy for Idiopathic Pulmonary Fibrosis . Past, Present, and Future Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1771 - 1777. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
